# US 2003/0215864 A1 · Compositions and methods related to two-arm nucleic acid probes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0215864 A1
- Document ID: US20030215864A1
- Status: Published application
- Kind: A1
- Application number: 10/421,644
- Filed: 2003-04-23
- Published: 2003-11-20
- Earliest claimed: 2002-04-23
- Assignees: U.S. Genomics, Inc.
- Inventors: Rudolf Gilmanshin; Nuno Goncalves
- Web page: https://patentgrep.com/patent/US20030215864A1

## CPC

- C40B 40/06: Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C12Q 1/6839: Triple helix formation or other higher order conformations in hybridisation assays
- C40B 30/04: by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
- C12Q 1/6816: characterised by the detection means (C12Q1/6804 takes precedence)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention provides compositions and methods of use relating to nucleic acid detection probes that comprise a Hoogsteen binding arm and a Watson-Crick binding arm that bind to adjacent but not identical target sites.

## Claims

### Claim 1

A composition comprising
a Hoogsteen binding arm that binds by Hoogsteen base pairing to a target nucleic acid molecule at a first target site, and
a Watson-Crick binding arm that binds by Watson-Crick base pairing to the target nucleic acid molecule at a second target site,
wherein the Hoogsteen binding arm and the Watson-Crick binding arm are conjugated to each other, and are comprised of nucleic acid or nucleic acid mimic elements.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the Hoogsteen binding arm is selected from the group consisting of a DNA, an RNA, a PNA, and an LNA.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the Watson-Crick binding arm is selected from the group consisting of a DNA, an RNA, a PNA, and an LNA.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the target nucleic acid molecule is a DNA or an RNA.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the Hoogsteen binding arm has at least one backbone modification.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the Watson-Crick binding arm has at least one backbone modification.

### Claim 7 (depends on 5, 6)

The composition of claim 5 or 6, wherein the at least one backbone modification is selected from the group consisting of a peptide modification, and a phosphorothioate modification.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the Hoogsteen binding arm and the Watson-Crick binding arm are conjugated to each other covalently.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the Hoogsteen binding arm and the Watson-Crick binding arm are conjugated to each other using a linker molecule.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the linker molecule is selected from the group consisting of 8-amino-3,6-dioxaoctanoic acid (O-linker), E-linker, and X-linker.

### Claim 11 (depends on 9)

The composition of claim 9, wherein the linker molecule comprises a cleavable bond.

### Claim 12 (depends on 9)

The composition of claim 9, wherein the linker molecule has a length of less than 100 Angstroms.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the Hoogsteen binding arm has a nucleotide sequence that is a homopurine nucleotide sequence or homopyrimidine nucleotide sequence.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the Watson-Crick binding arm has a nucleotide sequence that is random.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the Hoogsteen binding arm is 5-12 nucleotides in length.

### Claim 16 (depends on 1)

The composition of claim 1, wherein the Watson-Crick binding arm is 5-12 nucleotides in length.

### Claim 17 (depends on 1)

The composition of claim 1, wherein the Hoogsteen binding arm and the Watson-Crick binding arm have different lengths.

### Claim 18 (depends on 1)

The composition of claim 1; wherein the first target site and the second target site are spaced apart from each other by a distance selected from the group consisting of 1 base pair, 2 base pairs, 5 base pairs, 7 base pairs, 10 base pairs, 20 base pairs, and 25 base pairs.

### Claim 19 (depends on 1)

The composition of claim 1, wherein the Hoogsteen binding arm and the Watson-Crick binding arm, when both are bound to their respective target sites, are spaced apart from each other by a distance selected from the group consisting of 1 base pair, 2 base pairs, 5 base pairs, 7 base pairs, 10 base pairs, 20 base pairs, and 25 base pairs.

### Claim 20 (depends on 1)

The composition of claim 1, wherein the Hoogsteen binding arm is conjugated to an agent.

### Claim 21 (depends on 1, 20)

The composition of claim 1 or 20, wherein the Watson-Crick binding arm is conjugated to an agent.

### Claim 22 (depends on 20, 21)

The composition of claim 20 or 21, wherein the agent is a detectable label.

### Claim 23 (depends on 22)

The composition of claim 22, wherein the detectable label is selected from the group consisting of an electron spin resonance molecule (e.g., nitroxyl radicals), a fluorescent molecule, a chemiluminescent molecule, a radioisotope, an enzyme substrate, a biotin molecule, an avidin molecule, an electrical charge transferring molecule, a semiconductor nanocrystal, a semiconductor nanoparticle, a colloid gold nanocrystal, a ligand, a microbead, a magnetic bead, a paramagnetic particle, a quantum dot, a chromogenic substrate, an affinity molecule, a protein, a peptide, a nucleic acid, a carbohydrate, an antigen, a hapten, an antibody, an antibody fragment, and a lipid.

### Claim 24 (depends on 22)

The composition of claim 22, wherein the detectable label is detected using a detection system selected from the group consisting of a charge coupled device detection system, an electron spin resonance detection system, a fluorescent detection system, an electrical detection system, a photographic film detection system, a chemiluminescent detection system, an enzyme detection system, an atomic force microscopy (AFM) detection system, a scanning tunneling microscopy (STM) detection system, an optical detection system, a nuclear magnetic resonance (NMR) detection system, a near field detection system, and a total internal reflection (TIR) detection system.

### Claim 25 (depends on 20, 21)

The composition of claim 20 or 21, wherein the agent is a cytotoxic agent.

### Claim 26 (depends on 1)

The composition of claim 1, wherein the target nucleic acid molecule is a genomic DNA molecule or a mitochondrial DNA molecule.

### Claim 27

A composition comprising
a Hoogsteen binding arm that binds by Hoogsteen base pairing to a target nucleic acid molecule at a first target site, and
a Watson-Crick binding arm that binds by Watson-Crick base pairing to the target nucleic acid molecule at a second target site
wherein the Hoogsteen binding arm and the Watson-Crick binding arm are conjugated to each other through a linker.

### Claim 28 (depends on 1, 27)

A method for labeling a target nucleic acid molecule comprising
a) contacting the target nucleic acid molecule with a composition of claim 1 or 27, and
b) allowing the composition to bind specifically to the target nucleic acid molecule.

### Claim 29 (depends on 28)

The method of claim 28, further comprising detecting binding of the composition to the target nucleic acid molecule.

### Claim 30 (depends on 28)

The method of claim 28, wherein the Hoogsteen binding arm is selected from the group consisting of a DNA, an RNA, a PNA, and an LNA.

### Claim 31 (depends on 28)

The method of claim 28, wherein the Watson-Crick binding arm is selected from the group consisting of a DNA, an RNA, a PNA, and an LNA.

### Claim 32 (depends on 28)

The method of claim 28, wherein the Hoogsteen binding arm has at least one backbone modification.

### Claim 33 (depends on 28)

The method of claim 28, wherein the Watson-Crick binding arm has at least one backbone modification.

### Claim 34 (depends on 32, 33)

The method of claim 32 or 33, wherein the at least one backbone modification is selected from the group consisting of a peptide modification and a phosphorothioate modification.

### Claim 35 (depends on 28)

The method of claim 28, wherein the Hoogsteen binding arm and Hoogsteen binding arm are conjugated to each other covalently.

### Claim 36 (depends on 28)

The method of claim 28, wherein the Hoogsteen binding arm and Hoogsteen binding arm are conjugated to each other using a linker molecule.

### Claim 37 (depends on 36)

The method of claim 36, wherein the linker molecule is selected from the group consisting of 8-amino-3,6-dioxaoctanoic acid (O-linker), E-linker, and X-linker.

### Claim 38 (depends on 36)

The method of claim 36, wherein the linker molecule comprises a hydrolyzable cleavable.

### Claim 39 (depends on 36)

The method of claim 36, wherein the linker molecule has a length of less than 100 Angstroms.

### Claim 40 (depends on 28)

The method of claim 28, wherein the Hoogsteen binding arm has a nucleotide sequence that is a homopurine nucleotide sequence or homopyrimidine nucleotide sequence.

### Claim 41 (depends on 28)

The method of claim 28, wherein the Watson-Crick binding arm has a nucleotide sequence that is random.

### Claim 42 (depends on 28)

The method of claim 28, wherein the Hoogsteen binding arm is 5-12 nucleotides in length.

### Claim 43 (depends on 28)

The method of claim 28, wherein the Watson-Crick binding arm is 5-12 nucleotides in length.

### Claim 44 (depends on 28)

The method of claim 28, wherein the Hoogsteen binding arm and the Watson-Crick binding arm have different lengths.

### Claim 45 (depends on 28)

The method of claim 28, wherein the first target site and the second target site are spaced apart from each other by a distance selected from the group consisting of 1 base pair, 2 base pairs, 5 base pairs, 7 base pairs, 10 base pairs, 20 base pairs, and 25 base pairs.

### Claim 46 (depends on 28)

The method of claim 28, wherein the Hoogsteen binding arm and the Watson-Crick binding arm, when both are bound to their respective target sites, are spaced apart from each other by a distance selected from the group consisting of 1 base pair, 2 base pairs, 5 base pairs, 7 base pairs, 10 base pairs, 20 base pairs, and 25 base pairs.

### Claim 47 (depends on 28)

The method of claim 28, wherein the Hoogsteen binding arm is conjugated to an agent.

### Claim 48 (depends on 28, 47)

The method of claim 28 or 47, wherein the Watson-Crick binding arm is conjugated to an agent.

### Claim 49 (depends on 47, 48)

The method of claim 47 or 48, wherein the agent is a detectable label.

### Claim 50 (depends on 49)

The method of claim 49, wherein the detectable label is selected from the group consisting of an electron spin resonance molecule (e.g., nitroxyl radicals), a fluorescent molecule, a chemiluminescent molecule, a radioisotope, an enzyme substrate, a biotin molecule, an avidin molecule, an electrical charge transferring molecule, a semiconductor nanocrystal, a semiconductor nanoparticle, a colloid gold nanocrystal, a ligand, a microbead, a magnetic bead, a paramagnetic particle, a quantum dot, a chromogenic substrate, an affinity molecule, a protein, a peptide, a nucleic acid, a carbohydrate, an antigen, a hapten, an antibody, an antibody fragment, and a lipid.

### Claim 51 (depends on 49)

The method of claim 49, wherein the detectable label is detected using a detection system selected from the group consisting of a charge coupled device detection system, an electron spin resonance detection system, a fluorescent detection system, an electrical detection system, a photographic film detection system, a chemiluminescent detection system, an enzyme detection system, an atomic force microscopy (AFM) detection system, a scanning tunneling microscopy (STM) detection system, an optical detection system, a nuclear magnetic resonance (NMR) detection system, a near field detection system, and a total internal reflection (TIR) detection system.

### Claim 52 (depends on 47, 48)

The method of claim 47 or 48, wherein the agent is a cytotoxic agent.

### Claim 53 (depends on 48)

The method of claim 48, wherein the agent is a nucleic acid cleaving agent.

### Claim 54 (depends on 28)

The method of claim 28, wherein the target nucleic acid molecule is a DNA or an RNA molecule.

### Claim 55 (depends on 28)

The method of claim 28, wherein the target nucleic acid molecule is a genomic DNA molecule or a mitochondrial DNA molecule.

### Claim 56 (depends on 29)

The method of claim 29, further comprising determining a pattern of binding of the composition to the target nucleic acid molecule.

### Claim 57 (depends on 56)

The method of claim 56, wherein the pattern of binding is determined using a linear polymer analysis system, FISH, or optical mapping.

### Claim 58 (depends on 56)

The method of claim 56, wherein the pattern of binding is determined by detecting and measuring cleavage products from the target nucleic acid molecule.

### Claim 59 (depends on 56)

The method of claim 56, wherein the pattern of binding is indicative of a loss of transcription.

### Claim 60 (depends on 1)

The composition of claim 1, wherein the Hoogsteen binding arm comprises a PNA.

### Claim 61 (depends on 1, 60)

The composition of claim 1 or claim 60, wherein the Watson-Crick binding arm comprises a PNA.

### Claim 62 (depends on 28)

The method of claim 28, wherein the Hoogsteen binding arm comprises a PNA.

### Claim 63 (depends on 28)

The method of claim 28, wherein the Watson-Crick binding arm comprises a PNA.
